Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents

被引：83

作者：

Alyassin, Yasmine ^{[1
]}

Sayed, Elshaimaa G. ^{[1
,2
]}

Mehta, Prina ^{[1
]}

Ruparelia, Ketan ^{[1
]}

Arshad, Muhammad S. ^{[1
]}

Rasekh, Manoochehr ^{[1
,3
]}

Shepherd, Jennifer ^{[4
]}

Kucuk, Israfil ^{[5
]}

Wilson, Philippe B. ^{[6
]}

Singh, Neenu ^{[1
]}

Chang, Ming-Wei ^{[7
]}

Fatouros, Dimitrios G. ^{[8
]}

Ahmad, Zeeshan ^{[1
]}

机构：

[1] De Montfort Univ, Leicester Sch Pharm, Leicester LE1 9BH, Leics, England

[2] Menia Univ, Dept Pharmaceut, Fac Pharm, Al Minya, Egypt

[3] Brunel Univ London, Coll Engn Design & Phys Sci, Uxbridge UB8 3PH, Middx, England

[4] Univ Leicester, Dept Engn, Leicester LE1 7RH, Leics, England

[5] Gebze Tech Univ, Inst Nanotechnol, TR-41400 Gebze, Turkey

[6] Nottingham Trent Univ, Sch Anim Rural & Environm Sci, Brackenhurst Campus, Southwell NG25 0QF, England

[7] Univ Ulster, Nanotechnol & Integrated Bioengn Ctr, Jordanstown Campus, Newtownabbey BT37 0QB, North Ireland

[8] Aristotle Univ Thessaloniki, Dept Pharmaceut Technol, Sch Pharm, Thessaloniki 54124, Greece

来源：

DRUG DISCOVERY TODAY | 2020年 / 25卷 / 08期

关键词：

CO-DELIVERY; CONTROLLED-RELEASE; IN-VITRO; CANCER; THERAPY; SYSTEMS; DOXORUBICIN; PACLITAXEL; NANOTECHNOLOGY; NANOCARRIERS;

D O I：

10.1016/j.drudis.2020.06.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Recently, remarkable efforts have focused on research towards enhancing and delivering efficacious and advanced therapeutic agents. Even though this involves significant challenges, innovative techniques and materials have been explored to overcome these. The advantageous properties of mesoporous silica nanoparticles (MSNs), such as unique morphologies and geometries, makes then favorable for use for various drug delivery targeting purposes, particularly in cancer therapy. As we discuss here, MSNs have been utilized over the past few decades to improve the efficiency of anticancer drugs by enhancing their solubility to render them suitable for application, reducing adverse effects, and improving their anticancer cytotoxic efficiency.

引用

页码：1513 / 1520

页数：8

共 72 条

[21] Comparative study of two silica mesoporous materials (SBA-16 and SBA-15) modified with a hydroxyapatite layer for clindamycin controlled delivery [J].

Gonzalez, Gema ;

Sagarzazu, Amaya ;

Cordova, Amaia ;

Elena Gomes, Maria ;

Salas, Janet ;

Contreras, Leglys ;

Noris-Suarez, Karem ;

Lascano, Luis .

MICROPOROUS AND MESOPOROUS MATERIALS, 2018, 256 :251-265

[22] Mesoporous Silica Nanomaterials: Versatile Nanocarriers for Cancer Theranostics and Drug and Gene Delivery [J].

Kesse, Samuel ;

Boakye-Yiadom, Kofi Oti ;

Ochete, Belynda Owoya ;

Opoku-Damoah, Yaw ;

Akhtar, Fahad ;

Filli, Mensura Sied ;

Farooq, Muhammad Asim ;

Aquib, Md ;

Mily, Bazezy Joelle Maviah ;

Murtaza, Ghulam ;

Wang, Bo .

PHARMACEUTICS, 2019, 11 (02)

[23] Facile Synthesis of Monodispersed Mesoporous Silica Nanoparticles with Ultralarge Pores and Their Application in Gene Delivery [J].

Kim, Mi-Hee ;

Na, Hee-Kyung ;

Kim, Young-Kwan ;

Ryoo, Soo-Ryoon ;

Cho, Hae Sung ;

Lee, Kyung Eun ;

Jeon, Hyesung ;

Ryoo, Ryong ;

Min, Dal-Hee .

ACS NANO, 2011, 5 (05) :3568-3576

[24] Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities [J].

Kirtane, Ameya R. ;

Kalscheuer, Stephen M. ;

Panyam, Jayanth .

ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (13-14) :1731-1747

[25] Multidrug resistance (MDR) in cancer - Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs [J].

Krishna, R ;

Mayer, LD .

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 11 (04) :265-283

[26] Mesoporous silica nanoparticle based enzyme responsive system for colon specific drug delivery through guar gum capping [J].

Kumar, Balmiki ;

Kulanthaivel, Senthilguru ;

Mondal, Animesh ;

Mishra, Smruti ;

Banerjee, Biplab ;

Bhaumik, Asim ;

Banerjee, Indranil ;

Giri, Supratim .

COLLOIDS AND SURFACES B-BIOINTERFACES, 2017, 150 :352-361

[27] Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment [J].

Li, Chun ;

Hu, Junqing ;

Li, Wenyao ;

Song, Guosheng ;

Shen, Jia .

BIOMATERIALS SCIENCE, 2017, 5 (01) :77-88

[28] Polyvalent Mesoporous Silica Nanoparticle-Aptamer Bioconjugates Target Breast Cancer Cells [J].

Li, Le-Le ;

Yin, Qian ;

Cheng, Jianjun ;

Lu, Yi .

ADVANCED HEALTHCARE MATERIALS, 2012, 1 (05) :567-572

[29] Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery [J].

Li, Zhe ;

Zhang, Yongtai ;

Feng, Nianping .

EXPERT OPINION ON DRUG DELIVERY, 2019, 16 (03) :219-237

[30] PEGylated Lipid bilayer coated mesoporous silica nanoparticles for co-delivery of paclitaxel and curcumin: Design, characterization and its cytotoxic effect [J].

Lin, Jiahao ;

Cai, Qiang ;

Tang, Yinian ;

Xu, Yanjun ;

Wang, Qian ;

Li, Tingting ;

Xu, Huihao ;

Wang, Shuaiyu ;

Fan, Kai ;

Liu, Zhongjie ;

Jin, Yipeng ;

Lin, Degui .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2018, 536 (01) :272-282

← 1 2 3 4 5 6 7 8 →